Muether, Philipp Sebastian <br/><br/>
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity.  [electronic resource] 

 -  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie  May 2011 
 - 633-7 p.  digital 
<br/><br/> Publication Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1435-702X 
<br/><br/><label>Standard No.: </label>10.1007/s00417-010-1520-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Male<br/>Prospective Studies<br/>Ranibizumab<br/>Recurrence<br/>Retina--pathology<br/>Retreatment<br/>Time Factors<br/>Tomography, Optical Coherence<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vision Disorders--physiopathology<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--diagnosis